General Atlantic has pared its stake in Rubicon Research ahead of the pharma company’s ₹1,085 crore IPO, raising ₹140 crore through a share sale. The IPO includes a fresh issue and offer-for-sale, with proceeds earmarked for debt repayment, acquisitions, and growth plans.
